Kate Maclagan

Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention

Daniel L. Rolnik, Min Yi Tan, Argyro Syngelaki, David Wright et autres

au, gb, hk (code pays fourni par la source)

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases

Christine Girges, Nirosen Vijiaratnam, Alexa King, Grace Auld et autres

gb, au (code pays fourni par la source)

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early‐ to Mid‐Stage Parkinson's Disease Modification Trials

Nirosen Vijiaratnam, Christine Girges, Dilan Athauda, Alexa King et autres

gb (code pays fourni par la source)

Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia

Moritz Döbert, Anna Nektaria Varouxaki, An Chi Mu, Argyro Syngelaki et autres

gb, us, es, be (code pays fourni par la source)

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau et autres

gb (code pays fourni par la source)

Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial

Anoop Rehal, Z. Benkő, C. de Paco Matallana, Argyro Syngelaki et autres

gb, es, bg, it, be (code pays fourni par la source)

Early Vaginal Progesterone Versus Placebo in Twin Pregnancies for Prevention of Spontaneous Preterm Birth (EVENTS): A Randomised Double-Blind Trial

Anoop Rehal, Z. Benkő, C. de Paco Matallana, Argyro Syngelaki et autres

gb, es, bg, it, be (code pays fourni par la source)

Phase 3 trial of exenatide for Parkinson’s disease

Grace Auld, Kate Maclagan

Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

Adrian J. Hobbs, Amie J. Moyes, Reshma S. Baliga, Dipa Ghedia et autres

gb (code pays fourni par la source)

Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda, Kate Maclagan, Skene SS, Martha Bajwa-Joseph et autres

Post hoc analysis of the Exenatide‐ PD trial—Factors that predict response

Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri et autres

gb, us (code pays fourni par la source)

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri et autres

gb, us (code pays fourni par la source)